Valoctocogene roxaparvovec: Difference between revisions
CSV import |
CSV import |
||
| Line 28: | Line 28: | ||
__NOINDEX__ | __NOINDEX__ | ||
{{No image}} | {{No image}} | ||
__NOINDEX__ | |||
Latest revision as of 02:36, 18 March 2025
Valoctocogene Roxaparvovec (also known as BMN 270) is an experimental gene therapy treatment for Hemophilia A. It is being developed by BioMarin Pharmaceutical Inc.
Etymology[edit]
The name "Valoctocogene Roxaparvovec" is derived from the components of the therapy. "Valo" refers to the valine amino acid used in the therapy, "octo" refers to factor VIII, which the therapy aims to increase, "gene" refers to the gene therapy aspect of the treatment, "roxaparvo" is derived from the adeno-associated virus serotype 5 (AAV5) used as a vector in the therapy, and "vec" is short for vector.
Mechanism of Action[edit]
Valoctocogene Roxaparvovec works by delivering a functional copy of the factor VIII gene to the patient's liver cells using an AAV5 vector. This allows the liver cells to produce a continuous supply of factor VIII, which is deficient in people with Hemophilia A.
Clinical Trials[edit]
As of 2021, Valoctocogene Roxaparvovec is in Phase 3 clinical trials. The therapy has shown promise in early trials, with patients experiencing increased levels of factor VIII and decreased bleeding episodes.
